8-K: STAAR Surgical Q2 Sales Plunge 55% Amid China Inventory

STAAR Surgical reported a 55% year-over-year decline in second-quarter net sales to $44.3 million, primarily due to a planned reduction of channel inventory in China, resulting in a net loss of $(16.8) million.

Summary

• Net sales for Q2 2025 were $44.3 million, a 55% decrease compared to $99.0 million in Q2 2024.
• Excluding China, net sales increased by 10% year-over-year to $39.0 million.
• Gross margin was 74.0% in Q2 2025, down from 79.2% in Q2 2024 but up from 65.8% in Q1 2025.
• The company reported a net loss of $(16.8) million, or $(0.34) per diluted share, compared to net income of $7.4 million, or $0.15 per diluted share, in Q2 2024.
• Adjusted EBITDA loss was $(14.9) million, or $(0.30) per share, a significant decline from Adjusted EBITDA income of $22.5 million, or $0.45 per share, in Q2 2024.
• Total operating expenses decreased to $62.8 million from $66.5 million in the prior-year quarter, driven by cost optimization efforts.
• Restructuring, impairment, and related charges of $5.2 million were incurred in Q2 2025, primarily for severance and asset impairment.
• Cash, cash equivalents, and investments available for sale totaled $189.9 million as of June 27, 2025, down from $222.8 million at the end of Q1 2025.
• The company repurchased approximately 261,000 shares for $4.5 million at an average price of $17.17 per share under its $30 million share repurchase program.
• As of August 1, 2025, 376,000 shares have been purchased for a total of $6.5 million.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant year-over-year declines in net sales, net income, and EBITDA, despite sequential improvements and growth outside China. The substantial net loss and operating loss are concerning. The pending acquisition by Alcon introduces a major external factor, but the underlying operational performance for the quarter is weak.

Positives

• Net sales excluding China increased by 10% year-over-year to $39.0 million, indicating growth in other regions.
• Gross profit margin improved sequentially to 74.0% in Q2 2025 from 65.8% in Q1 2025.
• Total operating expenses decreased year-over-year due to ongoing cost optimization efforts.
• General and administrative expenses decreased to $21.0 million from $23.6 million in the prior-year quarter, primarily due to decreased outside services expenses.
• Selling and marketing expenses decreased to $26.3 million from $31.0 million in the prior-year quarter due to lower marketing, promotional, and advertising activities.
• Research and development expenses decreased to $10.3 million from $11.9 million in the prior-year quarter, primarily due to lower salary-related expenses.
• The company has no outstanding debt.
• The company is actively repurchasing shares under its $30 million program, demonstrating commitment to shareholder returns.

Negatives

• Overall net sales decreased by 55% year-over-year to $44.3 million.
• The company reported a net loss of $(16.8) million in Q2 2025, a significant decline from net income of $7.4 million in Q2 2024.
• Adjusted EBITDA shifted to a loss of $(14.9) million from an income of $22.5 million in the prior-year quarter.
• Operating income shifted to a loss of $(30.0) million from an income of $11.9 million in the prior-year quarter.
• The significant decline in China revenue, driven by distributors utilizing existing inventory, negatively impacted overall sales.
• Cash, cash equivalents, and investments available for sale decreased by $32.9 million from the end of Q1 2025.

Risks

• Ability to continue growth and profitability trajectory is uncertain.
• Reliance on independent distributors in international markets poses a risk.
• A slowdown or disruption to the Chinese economy could further impact sales.
• Global economic conditions may adversely affect demand.
• Disruptions in the supply chain could impact operations.
• Fluctuations in foreign currency exchange rates can affect financial results.
• International trade disputes, including tariffs, and substantial dependence on demand from Asia are ongoing concerns.
• Changes in effective tax rate or tax laws could impact profitability.
• Any loss of use of the principal manufacturing facility could disrupt production.
• Competition in the ophthalmic surgery market is a constant threat.
• Potential losses due to product liability claims are a risk.
• Exposure to environmental liability exists.
• Data corruption, cyber-based attacks, network security breaches, and noncompliance with data protection and privacy regulations are potential threats.
• Acquisitions of new technologies may not yield expected benefits.
• Climate changes could impact operations or supply chain.
• The willingness of surgeons and patients to adopt new or improved products and procedures is crucial for growth.
• Extensive clinical trials and resources devoted to research and development require significant investment.
• Compliance with government regulations is complex and costly.
• Regulatory agencies have discretion to approve or reject products, or require additional actions.
• Laws pertaining to healthcare fraud and abuse could lead to penalties.
• Changes in FDA or international regulations related to product approval could impact market access.
• Product recalls or failures could damage reputation and sales.
• The timing of, and completion of, or failure to complete, the pending acquisition by Alcon Inc. introduces significant uncertainty.
• Disruption of management's attention from ongoing business operations due to the pending acquisition is a risk.
• The effect of the acquisition announcement on the ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others is a concern.

Future Outlook

The filing primarily focuses on past financial results and does not provide explicit forward-looking guidance or financial estimates for future periods. However, it mentions the pending acquisition by Alcon Inc. as a significant future event that will impact the company's operations and reporting, leading to the cancellation of the Q2 2025 conference call.

Management Comments

• The year-over-year decrease in net sales was mainly driven by a notable decline in revenue from China, as the Company's distributors in the region made minimal purchases during the quarter, opting to utilize existing in-country inventory to meet procedural demand.
• The year-over-year decrease in operating expenses was driven by ongoing cost optimization efforts that continued throughout the second quarter.

Industry Context

STAAR Surgical operates in the global ophthalmic surgery market, specializing in phakic IOLs for vision correction. The significant decline in sales, particularly in China, highlights the vulnerability of companies with high regional concentration and reliance on channel inventory management. Despite the overall decline, growth in sales outside China suggests underlying demand for EVO ICL products in other markets. The pending acquisition by Alcon Inc., a major player in eye care, indicates a potential consolidation trend or strategic move within the industry, possibly driven by market dynamics or the acquiring company's desire to expand its portfolio in advanced vision correction technologies.

Stakeholder Impact

• Shareholders face significant financial losses for the quarter, but the ongoing share repurchase program and pending acquisition by Alcon Inc. could provide future value or liquidity.
• Employees are impacted by restructuring and cost control initiatives, including severance associated with leadership structure realignment.
• Customers and suppliers may experience changes due to the pending acquisition by Alcon Inc., as mentioned in the risks related to maintaining relationships.

Next Steps

• Completion of the pending acquisition of STAAR Surgical Company by Alcon Inc.
• Continued execution of cost optimization efforts.
• Ongoing management of channel inventory, particularly in China.

Key Dates

Recommendation

While the reported financial results show a significant year-over-year decline in key metrics, particularly net sales and profitability, the primary driver for investor action is the pending acquisition by Alcon Inc. The filing explicitly states the acquisition is 'pending,' which suggests the stock price is likely already trading close to the anticipated acquisition price, making a strong 'buy' or 'sell' based solely on these quarterly results less relevant for a seasoned investor. The poor underlying performance, if the acquisition were not in play, would warrant a 'sell' or 'strong sell'. However, given the acquisition, the recommendation is 'hold' as investors await the finalization of the deal, which will dictate the ultimate value realization. There is no information on the acquisition terms in this filing to suggest an arbitrage opportunity.

Keywords

STAAR Surgical, STAA, SEC Filing, 8-K, Q2 2025 Results, Financial Report, Phakic IOLs, EVO ICL, Implantable Collamer Lenses, Vision Correction, Ophthalmic Surgery, Medical Devices, China Market, Inventory Reduction, Net Sales, Net Loss, Adjusted EBITDA, Share Repurchase, Alcon Acquisition